A Single Course of Anti-Cd3 Monoclonal Antibody hOKT3 1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years After Onset of Type 1 Diabetes
Diabetes - United States
doi 10.2337/diabetes.54.6.1763
Full Text
Open PDFAbstract
Available in full text
Date
May 25, 2005
Authors
Publisher
American Diabetes Association